Literature DB >> 22791731

Topiramate-induced psychosis: the picture at 12 months.

Anna Watkin1, Faouzi Alam, Qaiser Javed.   

Abstract

A 19-year-old white British man, not previously known to psychiatric services, presented with acute onset of florid psychotic symptoms. His symptoms included auditory hallucinations, misidentification of family members, thought interference and delusions of control. His level of distress was high and did not respond to verbal or medical de-escalation; therefore, he required nursing in seclusion. It was noted that he recently had an increase of his anti-epileptic medication to 100 mg topiramate twice per day. Topiramate was thought to be the cause of his psychosis and, consequently, was changed to phenytoin. Since discontinuation of the topiramate, his psychotic symptoms settled within 4 days and he was discharged shortly afterwards. He was monitored by the Early Intervention services. At 15-months post-discharge, there was no recurrence of any symptoms despite not receiving antipsychotic medication. To our knowledge, this is the first report that describes the progress of a patient past the initial psychotic episode. Therefore, we believe this is an important finding to report.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22791731      PMCID: PMC3028422          DOI: 10.1136/bcr.07.2010.3141

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

1.  Topiramate-induced psychosis.

Authors:  Dana Kober; Glen O Gabbard
Journal:  Am J Psychiatry       Date:  2005-08       Impact factor: 18.112

Review 2.  Therapeutic applications of glycosidic carbonic anhydrase inhibitors.

Authors:  Jean-Yves Winum; Sally-Ann Poulsen; Claudiu T Supuran
Journal:  Med Res Rev       Date:  2009-05       Impact factor: 12.944

3.  Benefits of topiramate treatment in a dual-diagnosis patient.

Authors:  Jason Miller; John Roache
Journal:  Psychosomatics       Date:  2009 Jul-Aug       Impact factor: 2.386

4.  Topiramate-induced psychosis in patients with essential tremor: report of 2 cases.

Authors:  Theresa A Zesiewicz; Archer Tullidge; Jonathan Tidwell; Kelly L Sullivan; Robert A Hauser
Journal:  Clin Neuropharmacol       Date:  2006 May-Jun       Impact factor: 1.592

Review 5.  Role of antiepileptic drugs in the management of eating disorders.

Authors:  Susan L McElroy; Anna I Guerdjikova; Brian Martens; Paul E Keck; Harrison G Pope; James I Hudson
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam.

Authors:  Marco Mula; Michael R Trimble; Josemir W Sander
Journal:  Epilepsia       Date:  2007-08-17       Impact factor: 5.864

7.  Adjunctive topiramate treatment for a refractory familial adolescent mania.

Authors:  For-Wey Lung; Chun-Lin Liu; Chien-Shu Wang; Dong-Sheng Tzeng
Journal:  World J Biol Psychiatry       Date:  2009       Impact factor: 4.132

8.  Topiramate in combat-related posttraumatic stress disorder.

Authors:  Christopher P Alderman; Linda C McCarthy; John T Condon; Anita C Marwood; Judith R Fuller
Journal:  Ann Pharmacother       Date:  2009-03-31       Impact factor: 3.154

Review 9.  Antiepileptic drugs and psychopathology of epilepsy: an update.

Authors:  Marco Mula; Francesco Monaco
Journal:  Epileptic Disord       Date:  2009-03-03       Impact factor: 1.819

10.  A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events.

Authors:  Andres M Kanner; Joanne Wuu; Edward Faught; William O Tatum; Aaron Fix; Jacqueline A French
Journal:  Epilepsy Behav       Date:  2003-10       Impact factor: 2.937

View more
  1 in total

1.  Topiramate-Induced Acute Psychotic Symptoms: A Case Report.

Authors:  Hamed Jafarpour; Alireza Razavi; Kamal Alaedini; Maryam Sefidgarnia; Davood Hosseini Talari
Journal:  Clin Neuropsychiatry       Date:  2020-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.